Abstract
In medical product development, there has been a growing interest in utilizing real-world data which have become abundant owing to advances in biomedical science, information technology and engineering. High-quality real-world data may be utilized to generate real-world evidence for regulatory or healthcare decision-making. We discuss propensity score-based approaches for leveraging patients from a real-world data source to construct a control group for a non-randomized comparative study or to augment a single-arm or randomized prospective investigational clinical study. The proposed propensity score-based approaches leverage real-world patients that are similar to those prospectively enrolled into the investigational clinical study in terms of baseline characteristics. Either frequentist or Bayesian inference can then be applied for outcome data analysis, with the option of down-weighting information from the real-world data source. Examples based on pre-market regulatory review experience are provided to illustrate the implementation of the proposed approaches.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chen, M.-H., Ibrahim, J.G.: Power prior distribution for regression models. Stat. Sci. 15(1), 46–60 (2000)
Chen, W.-C., Wang, C., Li, H., Lu, N., Tiwari, R., Xu, Y., Yue, L.Q.: Propensity score-integrated composite likelihood approach for augmenting the control arm of a randomized controlled trial by incorporating real-world data. J. Biopharm. Stat. 30(3), 508–520 (2020). https://doi.org/10.1080/10543406.2020.1730877
Ibrahim, J.G., Chen, M.-H., Gwon, Y., Chen, F.: The power prior: theory and applications. Stat. Med. 34(28), 3724–3749 (2015). https://doi.org/10.1002/sim.6728
Imbens, G.W., Rubin, D.B.: Causal Inference for Statistics, Social, and Biomedical Sciences. Cambridge University Press, New York (2015)
Inman, H.F., Bradley Jr., E.L.: The overlapping coefficient as a measure of agreement between probability distributions and point estimation of the overlap of two normal densities. Commun. Stat. Theory Methods 18(10), 3851–3874 (1989)
Langenskold, S., Rubin, D.B.: Outcome-free design of observational studies: peer influence on smoking. Les Annales d’Economie et de Statistique 91(92), 107–125 (2008)
Li, H., Mukhi, V., Lu, N., Xu, Y., Yue, L.Q.: A note on good practice of objective propensity score design for premarket nonrandomized medical device studies with an example. Stat. Biopharm. Res. 8(3), 282–286 (2016)
Lu, N., Xu, Y., Yue, L.Q.: Good statistical practice in utilizing real world data in a comparative study for premarket evaluation of medical devices. J. Biopharm. Stat. 29(4), 580–591 (2019)
Lu, N., Xu, Y., Yue, L.Q.: Some considerations on design and analysis plan on a nonrandomized comparative study utilizing propensity score methodology for medical device premarket evaluation. Stat. Biopharm. Res. 12(2), 155–163 (2020)
Rosenbaum, P.R., Rubin, D.B.: The central role of the propensity score in observational studies for causal effects. Biometrika 70(1), 41–55 (1983)
Rosenbaum, P.R., Rubin, D.B.: Reducing bias in observational studies using subclassification on the propensity score. JASA 79, 516–524 (1984)
Rubin, D.B.: Using propensity score to help design observational studies: application to the tobacco litigation. Health Serv. Outcomes Res. Method. 2, 169–188 (2001)
Rubin, D.B.: For objective causal inference, design trumps analysis. Ann. Appl. Stat. 2(3), 808–840 (2008)
Varin, C., Reid, N., Firth, D.: An overview of composite likelihood methods. Stat. Sin. 21, 5–42 (2011)
Wang, C., Li, H., Chen, W., Lu, N., Tiwari, R., Xu, Y., Yue, L.Q.: Propensity score-integrated power prior approach for incorporating real-world evidence in single-arm clinical studies. J. Biopharm. Stat. 29(5), 731–748 (2019)
Wang, C., Lu, N., Chen, W., Li, H., Tiwari, R., Xu, Y., Yue, L.Q.: Propensity score-integrated composite likelihood approach for incorporating real-world evidence in single-arm clinical studies. J. Biopharm. Stat. 30(3), 495–507 (2020). https://doi.org/10.1080/10543406.2019.1684309
Xu, Y., Lu, N., Yue, L.Q., Tiwari, R.: A study design for augmenting the control group in a randomized controlled trial: a quality process for interaction among stakeholders. Thera. Innov. Regul. Sci. 54(2), 269–274 (2020)
Yue, L.Q., Lu, N., Xu, Y.: Designing pre-market observational comparative studies using existing data as controls: challenges and opportunities. J. Biopharm. Stat. 24, 994–1010 (2014)
Yue, L.Q., Campbell, G., Lu, N., Xu, Y., Zuckerman, B.: Utilizing national and international registries to enhance pre-market medical device regulatory evaluation. J. Biopharm. Stat. 26(6), 1136–1145 (2016)
Acknowledgements
The authors would like to thank the three anonymous referees for their insightful comments, which resulted in a stronger manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Li, H., Chen, WC., Lu, N. et al. Novel statistical approaches and applications in leveraging real-world data in regulatory clinical studies. Health Serv Outcomes Res Method 20, 237–246 (2020). https://doi.org/10.1007/s10742-020-00218-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10742-020-00218-4